Literature DB >> 8547402

Multidrug resistance proteins and other drug transport-related resistance to natural product agents.

H J Broxterman1, G Giaccone, J Lankelma.   

Abstract

The term multidrug resistance is defined in this article as cellular resistance to anticancer agents due to a decreased concentration of active drug at the target sites that is caused by increased metabolism or altered transport or routing of the active drug species. Resistance related to alterations in the drug targets or apoptotic pathways is not discussed. Until recently multidrug resistance was associated almost exclusively with p-glycoprotein (Pgp)-overexpression. However, other non-Pgp-related mechanisms have been tracked down. It has been shown that transfection of the gene that encodes a novel drug transport protein, the multidrug resistance protein, induces cross-resistance for many multidrug resistance drugs as well as active transport of daunorubicin from tumor cells. Surprisingly, it has also been found that multidrug resistance protein mediates transport of negatively charged species that are not classic multidrug resistance drugs, such as leukotriene C4 and other glutathione conjugates as well as negatively charged dyes. It was therefore suggested that multidrug resistance protein is identical with the multispecific organic anion transporter. The transport rate of several positively charged drugs (vincristine, rhodamine-123, daunorubicin) by multidrug resistance protein appeared to be dependent on the cellular glutathione levels. Multidrug resistance protein seems to be constitutively expressed in normal tissues at a low level with few tissues having higher expression. Multidrug resistance protein overexpression in in vitro-selected MDR cell lines occurs relatively frequently in lung cancer and leukemia cell lines and often precedes Pgp overexpression. Differential expression has been demonstrated in tumor samples, which suggests a role in resistance to chemotherapy in at least certain tumor types. Modulation studies of multidrug resistance protein activity are still scarce. Other non-Pgp, non-multidrug resistance protein multidrug resistance mechanisms probably exist but have not been identified at the molecular level as yet.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547402     DOI: 10.1097/00001622-199511000-00011

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  10 in total

Review 1.  Diagnostics of multidrug resistance in cancer.

Authors:  G Szakács; K Jakab; F Antal; B Sarkadi
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

2.  Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression.

Authors:  R Maitra; P A Halpin; K H Karlson; R L Page; D Y Paik; M O Leavitt; B D Moyer; B A Stanton; J W Hamilton
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

3.  ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1.

Authors:  J Renes; E G de Vries; E F Nienhuis; P L Jansen; M Müller
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

4.  Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines.

Authors:  M J Welters; A M Fichtinger-Schepman; R A Baan; M J Flens; R J Scheper; B J Braakhuis
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

5.  Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1.

Authors:  B A P van Gorkom; H Timmer-Bosscha; S de Jong; D M van der Kolk; J H Kleibeuker; E G E de Vries
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

6.  Potent interaction of flavopiridol with MRP1.

Authors:  J H Hooijberg; H J Broxterman; G L Scheffer; C Vrasdonk; M Heijn; M C de Jong; R J Scheper; J Lankelma; H M Pinedo
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

7.  Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.

Authors:  Saman Maleki Vareki; Kowthar Y Salim; Wayne R Danter; James Koropatnick
Journal:  PLoS One       Date:  2018-01-24       Impact factor: 3.240

8.  Influence of doxorubicin on model cell membrane properties: insights from in vitro and in silico studies.

Authors:  Ana Catarina Alves; Aniket Magarkar; Miguel Horta; Jose L F C Lima; Alex Bunker; Cláudia Nunes; Salette Reis
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

Review 9.  Electrochemotherapy: An Alternative Strategy for Improving Therapy in Drug-Resistant SOLID Tumors.

Authors:  Maria Condello; Gloria D'Avack; Enrico Pierluigi Spugnini; Stefania Meschini
Journal:  Cancers (Basel)       Date:  2022-09-05       Impact factor: 6.575

10.  Cell death sensitization of leukemia cells by opioid receptor activation.

Authors:  Claudia Friesen; Mareike Roscher; Inis Hormann; Iduna Fichtner; Andreas Alt; Ralf A Hilger; Klaus-Michael Debatin; Erich Miltner
Journal:  Oncotarget       Date:  2013-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.